Case Details
- Citation: [2012] SGHC 253
- Title: Novartis AG and another v Ranbaxy (Malaysia) Sdn Bhd
- Court: High Court of the Republic of Singapore
- Date: 28 December 2012
- Case Number: Suit No 150 of 2011
- Judges: Lee Seiu Kin J
- Coram: Lee Seiu Kin J
- Plaintiffs/Applicants: Novartis AG and another
- Defendant/Respondent: Ranbaxy (Malaysia) Sdn Bhd
- Legal Areas: Patents and inventions
- Procedural Posture: Application for leave to amend patent claims
- Statutes Referenced: Evidence Act; Medicines Act; Patents Act
- Key Provisions: O 87A r 11(6) of the Rules of Court (Cap 322, R 5, 2006 Rev Ed); ss 83 and 84(3) of the Patents Act (Cap 221, 2005 Rev Ed); s 12A(3)(a) of the Medicines Act (Cap 176, 1985 Rev Ed)
- Patent at Issue: Patent No SG120119 (“Patent”)
- Relief Sought in Main Suit (context): Declarations of infringement if product licences are granted and products are imported/marketed
- Defence/Counterclaim (context): Invalidity for anticipation by prior art (DA1 and DA2)
- Amendment Objective (as stated): Enhance clarity, highlight inventive contributions, reduce number of claims, and distinguish claims from cited prior art
- Disputed Amendments (as agreed at hearing): Whether amendments to claims 1 and 5 are permissible; other amendments were consequential
- Counsel for Plaintiffs: Tony Yeo, D K Rozalynne PG Dato Asmali and Dora Tay (Drew and Napier LLC)
- Counsel for Defendant: Daniel Koh (Eldan Law LLP) (instructed) and Andrew Quirk (foreign counsel from Mirandah Law LLP)
- Judgment Length: 19 pages, 10,185 words
- Cases Cited: [2012] SGHC 253 (as listed in metadata)
Summary
Novartis AG and its exclusive licensee sought leave to amend the claims of their Singapore patent (Patent No SG120119) in the context of an infringement dispute with Ranbaxy (Malaysia) Sdn Bhd. The dispute arose because Ranbaxy intended to import and market “Starval Tablets” in Singapore, and under the Medicines Act it was required to notify the patent proprietor of the potential infringement risk and to provide a window for the proprietor to commence proceedings. Novartis commenced suit and, alongside the infringement action, applied to amend the patent claims.
The central legal question for the amendment application was whether the proposed claim amendments would “add matter” to the patent specification as filed, contrary to s 84(3)(a) of the Patents Act. The High Court (Lee Seiu Kin J) applied the well-established “Bonzel” test for added matter, endorsed in Singapore authorities, and assessed the amendments through the eyes of the skilled addressee by comparing the disclosure in the application as filed with the disclosure in the patent as amended.
What Were the Facts of This Case?
Novartis AG was the registered proprietor of the patent at issue, and the second plaintiff was its exclusive licensee. Ranbaxy, a pharmaceutical company, planned to import for marketing in Singapore pharmaceutical products known as Starval Tablets. The compositions relevant to Ranbaxy’s intended products were said to relate to Novartis’ patent rights.
Under s 12A(3)(a) of the Medicines Act, Ranbaxy was obliged to serve notices to the patent proprietor when applying to the Health Sciences Authority for product licences. The notices were designed to inform the patent proprietor that the products Ranbaxy intended to import and market could potentially infringe the patent. The statutory mechanism also required that the patent proprietor commence proceedings within a specified period—45 days—if it wished to assert its rights and obtain relief; otherwise, the product licences would be granted.
After receiving the requisite notice, Novartis commenced the suit. The plaintiffs sought declarations that the patent would be infringed if Ranbaxy’s products were imported and marketed in Singapore. Ranbaxy defended the claim and counterclaimed, asserting that the patent was invalid on the basis of anticipation by prior art. Two prior art documents were relied upon in the invalidity case, referred to in the judgment as DA1 and DA2.
In response to the infringement and invalidity pleadings, Novartis applied to amend the patent claims. The stated purposes of the amendments were to enhance clarity, highlight the inventive contributions of the patent, reduce the number of claims, and further distinguish the claims from the matter disclosed in the prior art references cited by Ranbaxy. At the hearing, counsel agreed that the dispute effectively turned on whether amendments to claims 1 and 5 were permissible; amendments to other claims were consequential to those changes.
What Were the Key Legal Issues?
The principal issue was whether the proposed amendments to the patent claims would contravene s 84(3)(a) of the Patents Act by resulting in the specification disclosing “additional matter.” This issue is distinct from the substantive validity question (anticipation) that Ranbaxy raised in its defence and counterclaim. In other words, the court was not deciding whether the patent was invalid for anticipation at this stage; it was deciding whether the patentee could amend the claims without impermissibly improving its position by adding subject matter not disclosed in the application as filed.
Accordingly, the court had to apply the legal test for “added matter” in the context of patent amendments. The court needed to determine what the original application disclosed (explicitly and implicitly) and what the amended patent would disclose, and then compare the two disclosures strictly. The comparison had to be performed through the eyes of the skilled addressee, taking into account common general knowledge, and the court had to decide whether any relevant subject matter had been added unless it was clearly and unambiguously disclosed in the application as filed.
A secondary but related issue was the scope and effect of the agreed amendments. The parties accepted several background points: valsartan was an active agent for which a separate patent subsists; microcrystalline cellulose was an excipient that improves valsartan performance in a certain dosage; crospovidone was a disintegrant; and the patent concerned how valsartan is delivered and absorbed, not the chemical compound of valsartan itself. These concessions framed the technical context for assessing whether the amendments merely clarified or whether they introduced new technical features.
How Did the Court Analyse the Issues?
Lee Seiu Kin J began by setting out the statutory framework for amendments. The plaintiffs’ application was brought under s 83(1) of the Patents Act, which gives the court discretion to allow the proprietor to amend the specification in infringement or revocation proceedings, subject to s 84. However, that discretion is constrained by s 84(3), which prohibits amendments that (a) result in the specification disclosing additional matter, or (b) extend the protection conferred by the patent. In this application, only the “added matter” prohibition under s 84(3)(a) was germane.
To determine whether amendments disclose additional matter, the court relied on the “Bonzel” test from Bonzel (T) and anr v Intervention Limited and anr (No 3) [1991] RPC 553. The court emphasised that the task is threefold: first, to ascertain what the application as filed discloses (explicitly and implicitly) through the eyes of the skilled addressee; second, to do the same for the patent as granted (or as amended, in the relevant comparison); and third, to compare the two disclosures to decide whether any subject matter relevant to the invention has been added. The comparison is strict: subject matter will be added unless it is clearly and unambiguously disclosed in the application as filed.
The court noted that the Bonzel test had been endorsed in several Singapore cases, including FE Global Electronics Pte Ltd v Trek Technology (Singapore) Pte Ltd and another appeal [2006] 1 SLR(R) 874, Martek Biosciences Corp v Cargill International Trading Pte Ltd [2011] 4 SLR 429, and Main-Line Corporate Holdings Ltd v DBS Bank Ltd [2012] 4 SLR 147. The court further elaborated the approach by referencing European Central Bank v Document Security Systems Incorporated [2007] EWHC 600, particularly the points that (i) claims form part of the disclosure for construction purposes, (ii) the skilled addressee approach includes common general knowledge, (iii) the test is not an obviousness test, and (iv) the focus is on whether the amendment provides an unwarranted advantage by adding technical contribution not originally disclosed.
In applying these principles, the court had to construe both the original application and the proposed amended claims. The analysis required careful attention to the technical features of the claims, particularly those in claims 1 and 5, since the parties agreed that the permissibility of amendments to those claims was the real battleground. The proposed amendments, as reflected in the marked-up claim set, involved specific compositional and percentage ranges for microcrystalline cellulose and crospovidone, as well as the proportion of valsartan in free form and the weight ratio between valsartan and microcrystalline cellulose. These are not merely drafting changes; they potentially affect the technical scope of the claimed dosage form and therefore the disclosure comparison.
The court’s reasoning, as reflected in the extract, indicates a disciplined approach: it would not treat the amendments as permissible simply because they might be “obvious” to the skilled addressee or because they could be inferred from general knowledge. Instead, the amendments could only be allowed if the additional technical subject matter was clearly and unambiguously disclosed in the application as filed, either explicitly or implicitly. This is consistent with the policy rationale underlying the added matter rule: a patentee should not be allowed to improve its position by adding subject matter that was not originally disclosed, thereby undermining legal security for third parties who rely on the content of the original filing.
Although the provided extract truncates the remainder of the judgment, the structure of the analysis makes clear that the court would have proceeded to compare the original disclosure (including the specification and claims as filed) with the amended claim language, focusing on whether the amended ranges and compositional limitations were supported by the original disclosure. In pharmaceutical patents, where claims often turn on numerical ranges and formulation parameters, the added matter inquiry frequently turns on whether the original specification disclosed those ranges directly, or whether it disclosed a broader concept from which the narrower ranges could be derived only by selection or extrapolation. Under the Bonzel approach, such selection is not enough unless the narrower subject matter is clearly and unambiguously disclosed.
What Was the Outcome?
The extract provided does not include the final orders. However, the legal framework and the court’s identification of the decisive issue—whether amendments to claims 1 and 5 would add matter—indicate that the outcome depended on the strict disclosure comparison mandated by s 84(3)(a) and the Bonzel test. In practice, the court’s decision would determine whether Novartis could proceed with the amended claims in the ongoing infringement proceedings.
For practitioners, the practical effect of the outcome is straightforward: if leave to amend was granted, the amended claims would form the operative basis for assessing infringement and potentially for narrowing the scope of the patent away from the prior art relied upon by Ranbaxy. If leave was refused, the plaintiffs would have to rely on the unamended claims, leaving the infringement and validity issues to be determined on that narrower or broader claim set.
Why Does This Case Matter?
This case is a useful illustration of how Singapore courts approach patent amendments, particularly the “added matter” constraint in s 84(3)(a) of the Patents Act. The decision reinforces that amendment discretion is not unfettered: even where amendments are framed as clarifications or attempts to distinguish prior art, the court will scrutinise whether the patentee is effectively introducing new technical subject matter not disclosed in the original application.
For patent litigators and patent drafters, the case underscores the importance of ensuring that the original specification contains sufficient disclosure to support later claim refinement. In formulation and dosage form patents—where claim scope is often defined by percentage ranges, ratios, and compositional limitations—the added matter rule can be particularly challenging. A patentee cannot rely on arguments that the amended ranges are merely “obvious” or that they reflect what a skilled person would understand; the disclosure must be clearly and unambiguously present in the original filing.
From a litigation strategy perspective, the case also demonstrates the procedural interplay between Medicines Act notice mechanisms and patent enforcement. The statutory licensing notice creates a time-sensitive window for commencing infringement proceedings, while amendment applications can be used to manage claim scope in response to invalidity defences. However, amendment is constrained by the added matter rule, meaning that the ability to “respond” to prior art through amendments may be limited by what was originally disclosed.
Legislation Referenced
- Rules of Court (Cap 322, R 5, 2006 Rev Ed), O 87A r 11(6)
- Patents Act (Cap 221, 2005 Rev Ed), s 83 [CDN] [SSO]
- Patents Act (Cap 221, 2005 Rev Ed), s 84(3)(a) [CDN] [SSO]
- Medicines Act (Cap 176, 1985 Rev Ed), s 12A(3)(a) [CDN] [SSO]
- Evidence Act (referenced in metadata)
Cases Cited
- Bonzel (T) and anr v Intervention Limited and anr (No 3) [1991] RPC 553
- FE Global Electronics Pte Ltd and others v Trek Technology (Singapore) Pte Ltd and another appeal [2006] 1 SLR(R) 874
- Martek Biosciences Corp v Cargill International Trading Pte Ltd [2011] 4 SLR 429
- Main-Line Corporate Holdings Ltd v DBS Bank Ltd [2012] 4 SLR 147
- European Central Bank v Document Security Systems Incorporated [2007] EWHC 600
Source Documents
This article analyses [2012] SGHC 253 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.